News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OnSource Corporation (OSCE.OB) Executes Definitive Merger Agreement With Osmotics Pharma, Inc. (OPI); Provides For Entry Into Specialty Pharmaceuticals



10/19/2005 5:13:15 PM

BOULDER, Colo.--(BUSINESS WIRE)--April 12, 2005--OnSource Corporation ("OnSource") (OTCBB:OSCE) today announced that it executed a definitive agreement to merge (the "Merger Agreement") with Osmotics Pharma, Inc. ("OPI"). OPI is an emerging specialty pharmaceutical company focused on developing prescription products for the treatment of various dermatological disorders, antibiotic-resistant strains of bacteria and certain cancers. OPI has the exclusive worldwide rights covering technologies developed by the University of California and Brigham Young University ("BYU"). Applications of these technologies are currently being tested by some of the leading research institutions in the world. All of OPI's products are in the development stage and subject to approval by the United States Food and Drug Administration ("FDA"). OPI has filed its first application with the FDA on form 510(k) seeking marketing clearance for Epiceram, a topical barrier repair cream for treatment of atopic dermatitis, radiation dermatitis and several other indications.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES